1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 14:30 ET (18:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。